Desktop Scanners
PRODUCTS
-
Niche CRO with a difference
Worldwide Oncology is a niche oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation therapies to patients in need. Oncology clinical research is complex, demanding, and continually evolving. Bringing effective therapies to proof-of-concept and then to market as fast as possible is our passion because every second counts for patients with cancer and their families.
-
ATUM is building on DNA2.0's reputation for rapid, reliable and accurate DNA synthesis. Using our proprietary GeneGPS® and VectorGPS® platforms we design constructs optimized to express in your system, whether that's a single gene in E. coli, a metabolic pathway in yeast or a complex bispecific antibody in mammalian cells.
-
SimpleStep ELISA® kits are sandwich ELISA assays that we have developed to be as simple and effective as possible. Unlike traditional sandwich ELISAs, which take more than three hours to run, SimpleStep ELISA kits generate data in just 90 minutes without compromising performance, using only one wash step and recombinant antibodies for exceptional specificity.
-
The revolutionary ThermAer Process achieves the results you want without compromising quality or cost objectives.
-
Our model combines the depth and experience level of our people with effective tools and processes already in place that are designed to ensure your critical eTMF documents and content are secure, organized, readily accessible, and always in complete compliance with all relevant regulations.
WHITE PAPERS AND CASE STUDIES
-
Keeping The Lights On With Wolfspeed SiC
Introducing the “M” inverter, a modular, silicon carbide-based solution that optimizes utility-scale energy storage with higher efficiency, reliability, and scalability.
-
Efficient Carbon And Ion Exchange Media Exchange
This document outlines the essential steps required to exchange spent media, including disposal of spent media.
-
Organizational Assessment For A Large MedTech Company
Explore an organizational assessment run for a medical technology company specializing in tissue repair and regeneration, and the actionable recommendations provided to facilitate future growth.
-
Hot Water Disinfection For International Hotel Chain, Israel
See how an Israeli hotel chain slashed energy costs by 27% while ensuring Legionella compliance through innovative UV water disinfection technology.
-
Non-Viral Genetic Modification Using The 4D-Nucleofector LV Unit In CGT
This paper underscores the 4D-Nucleofector® LV Unit as a pivotal tool for translating genetic modification technologies into scalable, safe, and effective therapeutic solutions.
-
Delivering Water Biosecurity At Palma Aquarium Spain
Learn how Palma Aquarium safeguards its delicate marine ecosystem with Atlantium’s innovative HOD UV technology, preventing disease outbreaks and protecting the environment.
-
Using Plant Peptones To Boost Plasmid Yield And Induction
Uncover how Nu‑Tek’s plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.
-
Methods For Determining Equipment Capability Of Freeze-Dryers
Observe two experimental methods for determining choked flow: the minimum controllable pressure method and the choke point method.
-
Advancing ADCs With Expertise In Payloads And Linkers
Discover how integrated containment, high-potency expertise, advanced chromatography, and proven linker–payload process optimization can accelerate your ADC program from early development to reliable commercial supply.
-
Next Generation Sequencing In Viral Safety Testing
Next Generation Sequencing (NGS) offers a sensitive, high-throughput solution for detecting adventitious viral agents (AVAs), improving biopharmaceutical safety and accelerating regulatory-compliant product development.
-
Writing An IND Module 3 For Cell And Gene Therapy Products
This whitepaper outlines the critical considerations for CGT Investigational New Drug (IND) Module 3, as well as how to avoid clinical holds and ensure regulatory readiness.
-
Optimizing Poloxamer 188
Poloxamer 188 stabilizes proteins in liquid formulations and protects cells from shear stress. Molecular weight and hydrophobicity variations influence its effectiveness in different biopharmaceutical applications.
NEWS
-
Webfleet Introduces Its New Driver Terminal PRO X: A Rugged, High-Performance Tablet For Fleet Professionals3/31/2025
Webfleet, Bridgestone’s globally trusted fleet management solution, is introducing its new flagship Driver Terminal: the PRO X.
-
Pulseforge Achieves Record Photonic Debonding Orders In Q1 2025, Signaling Market Acceleration4/29/2025
PulseForge, Inc., a global leader in high-intensity pulsed-light systems for semiconductor manufacturing, today announced a record volume of photonic debonding equipment orders in the first quarter of 2025.
-
ArriVent BioPharma Enters Exclusive License With Lepu Biopharma For MRG007, An Antibody Drug Conjugate For The Treatment Of Gastrointestinal Cancers1/21/2025
ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers.
-
Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study2/12/2026
Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.
-
API Releases Bulletin Demonstrating The Suitability Of Portland Cement For CCUS Projects11/6/2025
The American Petroleum Institute (API) today announced the publication of API Bulletin 5100, Ordinary Portland Cement as a Barrier for Carbon Capture, Utilization, and Storage (CCUS) Applications.